Paving the TRAIL to anti‐fibrotic therapy
Maria Eugenia Guicciardi, Gregory J. Gores – 29 February 2016
Maria Eugenia Guicciardi, Gregory J. Gores – 29 February 2016
Meenakshisundaram Ananthanarayanan – 29 February 2016
Liu Yao, Chunjiong Wang, Xu Zhang, Liyuan Peng, Wenli Liu, Xuejiao Zhang, Yajin Liu, Jinlong He, Changtao Jiang, Ding Ai, Yi Zhu – 29 February 2016 – Hyperhomocysteinemia (HHcy) is associated with liver diseases such as fatty liver and hepatic fibrosis; however, the underlying mechanism is still largely unknown. The current study aimed to explore the signaling pathway involved in HHcy‐induced hepatic steatosis (HS). C57BL/6 mice were fed a high‐methionine diet (HMD) for 4 and 8 weeks to establish the HHcy mouse model.
Lisa M. McElroy, Elizabeth Z. Gillett, Cristina Nguyen, Jane L. Holl, Michael M. Abecassis, Daniela P. Ladner – 26 February 2016
Jagpal Singh Klair, Ju Dong Yang, Manal F. Abdelmalek, Cynthia D. Guy, Ryan M. Gill, Katherine Yates, Aynur Unalp‐Arida, Joel E. Lavine, Jeanne M. Clark, Anna Mae Diehl, Ayako Suzuki, for the Nonalcoholic Steatohepatitis Clinical Research Network – 26 February 2016 – Postmenopausal women with nonalcoholic steatohepatitis are at an increased risk of hepatic fibrosis compared with premenopausal women. Whether duration of estrogen deficiency in postmenopausal state dictates an individual's fibrosis risk remains uninvestigated.
Eleonora Patsenker, Felix Stickel – 26 February 2016
Shayon D. Salehi, Debbie L. Shawcross – 26 February 2016
Neeral L. Shah, Stephen H. Caldwell – 26 February 2016
Pranab M. Barman, Grace L. Su – 26 February 2016
Pranab M. Barman, Grace L. Su – 26 February 2016